ARION: what clinicians are saying
durvalumab in localised unresectable esophageal cancer · NCT03777813 ↗ · Phase 2 · UNICANCER
The clinicians cited read ARION as negative because reported outcomes did not improve, with one radiation oncologist qualifying that reading by the small, predominantly squamous cohort. That clinician reports frequent severe treatment-related toxicity but no safety signal, and regards the younger-patient survival observation as hypothesis-generating. Differences between numerical accounts remain unexplained. The sources place the phase II results at ESMO 2026.
Created with AI · how we check it
- edition 1
- commentary checked Nov 21, 2026
- 14 verified statements
This edition $750, with MCP access for your AI agent. Get this report
5 findings, and what sits behind each
01. ARION: why speakers see no significant PFS or OS benefit from adding durvalumab
2 of the report's 3 cited clinicians · 7 statements from 5 speakers in 5 sources, 1 of them a podcast or video · 5 passages
Limitations recorded: 3.
Draws on: Primary endpoint: cPFS (centrally reviewed cPFS), Secondary endpoint: Overall survival (OS), Population and setting, The comparison, Design and conduct.
02. ARION safety: most speakers see no new signal, but most flag severe toxicity
1 of the report's 3 cited clinicians · 3 statements from 3 speakers in 3 sources · 3 passages
Limitations recorded: 2.
Draws on: Secondary endpoint: Adverse Events, Safety and tolerability, Secondary endpoint: Overall survival (OS), Design and conduct.
03. Under-65 OS: speakers flag a signal, but a clinician calls it exploratory only
1 of the report's 3 cited clinicians · 5 statements from 3 speakers in 3 sources · 3 passages
Limitations recorded: 3.
Draws on: Secondary endpoint: Overall survival (OS), Secondary endpoint: Adverse Events, Safety and tolerability, Primary endpoint: cPFS (centrally reviewed cPFS), Population and setting, The comparison, Design and conduct.
04. ARION: a clinician views radiation as mostly immunosuppressive
1 of the report's 3 cited clinicians · 1 statement from 1 speaker in 1 source · 1 passage
Limitations recorded: 1.
Beyond the trial population
05. RT and systemic therapy: a speaker asks about integration across settings
No named clinician · accounts and unnamed speakers · 1 statement from 1 speaker in 1 source · 1 passage
Limitations recorded: 1.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 5
2 of the report's 3 cited clinicians
ARION: why speakers see no significant PFS or OS benefit from adding durvalumab
7 statements from 5 speakers in 5 sources, 1 of them a podcast or video
5 of the 5 named speakers in this finding hold this view
- 7
- statements
- 5
- passages
- 5
- sources
- 5
- speakers
What the statements areViews 4Questions and uncertainty 0Clinical experience 0Comparisons 1Restated results and context 2Statement-to-passage links (a passage can back several statements)Supporting a statement 8Giving context 0Recorded with the findingLimitations: 3
4 posts and articles · 1 podcast or video
Draws on: Primary endpoint: cPFS (centrally reviewed cPFS), Secondary endpoint: Overall survival (OS), Population and setting, The comparison, Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
1 of the 5 findings and 1 of the 14 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (7)
ESMO, European Society for Medical Oncology; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival; PFS, progression-free survival; RT, radiotherapy.
The full ARION report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What evidence do clinicians say is needed to determine whether adding durvalumab to definitive chemoradiotherapy improves overall survival in patients younger than 65 with localised unresectable oesophageal cancer, beyond ARION’s exploratory findings?
From finding F3 (5 statements from 3 speakers in 3 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 16commentary sources screened
- 6sources cited by verified statements
- 7named in screened sources
- 7speakers cited in the report
- 6cited speakers with a verified identity
3 cited clinicians, speakers with a confirmed clinical role, of them 3 physicians. By role and specialty:
- 2 physician, Radiation oncology
- 1 physician, Gastroenterology
- 14verified statements, each linked to its source
- 5of them from speakers with a confirmed clinical role
- 5findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 14 | Paid |
| Who said each statement: the cited speakers | 7 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 6 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
11 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: cPFS (centrally reviewed cPFS) | 6 | 5 |
| Secondary endpoint: Overall survival (OS) | 8 | 5 |
| Secondary endpoint: Adverse Events | 3 | 3 |
| Secondary endpoint: Quality of Life OES18, used for patients with oesophageal cancer always complemented by the QLQ-C30 measuring 5 functional scales (physical, everyday activity, cognitive, emotional and social) and 3 symptoms scales (fatigue, pain, nausea and vomiting)no commentary found | 0 | 0 |
| Population and setting | 5 | 5 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 5 | 5 |
| Safety and tolerability | 3 | 3 |
| Design and conduct | 4 | 3 |
| Younger-patient survival signal and patient-selection research | 4 | 3 |
| Other negative immunotherapy–chemoradiotherapy studies as interpretive context | 2 | 2 |
| Radiation's immunological interpretation | 1 | 1 |
| Cross-setting integration of radiotherapy and systemic treatment | 1 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
14 verified statements from 6 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 3 statements · 21% | ||||
| YouTube | 0 | 0 | 1 | |
| X videos | 3 | 1 | 1 | |
| Posts · 11 statements · 79% | ||||
| X threads | 7 | 3 | 12 | |
| LinkedIn posts | 4 | 2 | 2 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 14 / quarter
- Screened window
- Sep 22, 2026 → Nov 14, 2026
- Cited window
- Sep 30, 2026 → Nov 14, 2026
- Retrieved
- Nov 20, 2026
The trial
from ClinicalTrials.gov- Title
- Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial
- Also known as
- PRODIGE 67
- Registry
- NCT03777813
- Study IDs
- UC-110/1719 -PRODIGE 67-UCGI33 · 2018-000708-40
- Sponsor
- UNICANCER
- Design
- Phase 2 · Interventional, randomized, parallel
- Status
- Completed
- Enrollment
- 112 actual
- Registered
- 2018-12-17
- Start
- 2018-12-05 actual
- Primary completion
- 2024-05-24 actual
- Primary endpoint
- cPFS (centrally reviewed cPFS)
- Interventions
- 2 registered
More on: Esophageal cancer, durvalumab
Discussed at: ESMO Congress 2026
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 46 sources about other trials or topics are not included; discussion that uses 4 names the trial shares with other things, without the trial's condition or setting, may be missing.
- The sources reviewed for this edition are a limited set of public discussions, not a representative sample of treating clinicians; repeated circulation does not establish independent agreement.
- Discussion without the trial's names or identifiers, or using different wording or transcription variants, may be missing.
Show all 8 known gaps +Fewer −
- No protocol was listed in the trial's ClinicalTrials.gov record, and no results publication for this exact trial was identified. The report describes attributed accounts rather than independently reconciled efficacy and safety results.
- A speaker's and Martinez another speaker's hazard-ratio summaries differ without an explanation in their statements, so the estimates are not combined.
- The younger-patient survival observation remains a trend or exploratory signal, and the expected value of ancillary studies is prospective.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 21, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. ARION (NCT03777813): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/arion-nct03777813
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "ARION" (NCT03777813), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "arion-nct03777813". If you cannot make requests, read https://www.erudio.com/reports/arion-nct03777813.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT03777813", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT03777813 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/arion-nct03777813.json
curl https://www.erudio.com/reports/arion-nct03777813.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "arion-nct03777813" })release ada8382fe422a80c6bc75f4d17ce6455489f8b43fc1937f21bd495ba8a778a11
Questions
How much does the ARION report cost?
One edition costs $750 (Focused · 14 verified statements · 5 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the ARION report cover?
14 statements from 6 sources (1 video, 5 posts), 5 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the ARION report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "arion-nct03777813" }) previews it and create_order({ "report": "arion-nct03777813", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the ARION report?
Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.